Media Articles Related to Luxiq (Betamethasone Topical)
Source: MedicineNet Allergy Specialty [2013.03.28]
Title: Contact Dermatitis
Category: Diseases and Conditions
Created: 3/28/2013 5:49:00 PM
Last Editorial Review: 3/28/2013 5:49:47 PM
Source: MedicineNet betamethasone dipropionate Specialty [2012.08.03]
Title: Atopic Dermatitis
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 8/3/2012 12:00:00 AM
Eczema (Atopic Dermatitis) Pictures Slideshow: Causes, Symptoms and Treatment
Source: MedicineNet Skin Test For Allergy Specialty [2012.03.26]
Title: Eczema (Atopic Dermatitis) Pictures Slideshow: Causes, Symptoms and Treatment
Created: 3/26/2012 12:00:00 AM
Last Editorial Review: 3/26/2012 12:00:00 AM
Source: MedicineNet ciclopirox Specialty [2012.03.16]
Title: Seborrheic Dermatitis
Category: Diseases and Conditions
Created: 3/16/2012 5:47:00 PM
Last Editorial Review: 3/16/2012 5:47:54 PM
Picture of Atopic Dermatitis
Source: MedicineNet pimecrolimus Specialty [2010.12.15]
Title: Picture of Atopic Dermatitis
Created: 12/15/2010 6:54:00 PM
Last Editorial Review: 12/15/2010 6:54:33 PM
Published Studies Related to Luxiq (Betamethasone Topical)
Topical betamethasone and hyaluronidase in the treatment of phimosis in boys: a double-blind, randomized, placebo-controlled trial. [2011.05]
PURPOSE: To compare the efficacy of three different formulations containing Betamethasone Valerate versus placebo in the topical treatment of phimosis. As a secondary goal, we compared the outcomes after 30 and 60 days of treatment... CONCLUSIONS: Betamethasone Valerate 0.1%, 0.2% and 0.2% in combination with Hyaluronidase had equally higher results than placebo in the treatment of phimosis in boys from three to ten years-old. Patients initially with partial or no response can reach complete response after 60 days of treatment.
Doxepin cream vs betamethasone cream for treatment of chronic skin lesions due to sulfur mustard. [2011.05]
Oral doxepin was shown to reduce chronic pruritus due to sulfur mustard. The present study compared the effects of topical doxepin 5% with betamethasone 1% for the treatment of pruritus in veterans exposed to sulfur mustard...
Topical betamethasone and hyaluronidase in the treatment of phimosis in boys: a
double-blind, randomized, placebo-controlled trial. 
secondary goal, we compared the outcomes after 30 and 60 days of treatment... CONCLUSIONS: Betamethasone Valerate 0.1%, 0.2% and 0.2% in combination with
A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. [2010.08]
BACKGROUND: Data are lacking on the use of topical therapies in combination with tumour necrosis factor blockers for the treatment of psoriasis. OBJECTIVES: To assess the efficacy and safety of adalimumab (ADA) with topical calcipotriol/betamethasone (C/B) in patients with psoriasis resembling those treated in routine clinical practice... CONCLUSIONS: ADA + C/B resulted in more rapid and higher efficacy within the first 4 weeks; thereafter, the trend was towards a higher response with ADA monotherapy. There was no statistical difference in the PASI 75 response at week 16. Both treatment regimens were well tolerated.
Calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: a randomised, parallel group, double-blind, exploratory study. [2010.07]
A two-compound ointment containing calcipotriol plus betamethasone dipropionate is an effective treatment for psoriasis vulgaris. The same active ingredients have now been combined in a gel formulation... This exploratory study showed that the two-compound gel was safe and more efficacious than its individual ingredients in the treatment of psoriasis vulgaris.
Clinical Trials Related to Luxiq (Betamethasone Topical)
Safety and Efficacy of Quadriderme® in the Treatment of Impetiginous Eczema (Study P05134AM4) [Recruiting]
This is a parallel-group, randomized, active-controlled, double-blind, Phase 4 trial
comparing three creams in the treatment of impetiginous eczema:
- Arm A: QUADRIDERME® cream (betamethasone diproprionate, clotrimazole and gentamicin
- Arm B: Combination of betamethasone diproprionate cream and gentamicin sulfate cream
- Arm C: Betamethasone diproprionate cream
At 7 sites, in Portugal, a total of 207 subjects will be randomized using a 1: 1:1
randomization ratio to receive one of the three possible treatments for a maximum period of
28 days or until 5 days after total remission of the signs and symptoms, but never more than
28 days. Assessments will be made of level of improvement of the target area in each
treatment group, number of days for total remission, and safety profile.
Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Cortisosensitive Dermatosis [Not yet recruiting]
Topical corticosteroids are largely used in dermatology. The major problem related to their
use is that the same mechanisms underlying their therapeutic effects (antiinflammatory and
antiproliferative) may lead to adverse events. Conditions sensitive to corticosteroids
require formulations with mild to moderate potency while high-potency corticosteroids era
required in less responsive conditions. The aim of the present study is to compare the
safety and efficacy of prednisolone acetate 0. 5% cream (mild-potency non-fluoridated
corticosteroid) versus betamethasone valerate 0. 1% cream (high-potency fluoridated
corticosteroid) in the treatment of mild to moderate cortisosensitive dermatosis (atopic
dermatitis, contact dermatitis, seborrheic dermatitis and psoriasis). The study hypothesis
is that 0. 5% prednisolone cream will be as effective as 0. 1% betamethasone cream and will be
an alternative option to treat corticosensitive dermatosis in body areas where the use of
fluoridated corticosteroids is contraindicated, such as the face.
Efficacy and Safety of Calcipotriene/Betamethasone Gel/Ointment in Psoriasis [Completed]
Patients will receive either a gel containing both calcipotriene plus betamethasone or gel
with no active ingredients as treatment for their scalp psoriasis for 8 weeks. After this
time all patients will receive the gel containing both calcipotriene and betamethasone for 44
weeks. In addition, patients will receive an ointment containing both calcipotriene plus
betamethasone as treatment for their psoriasis of the trunk and limbs for 52 weeks.
The objective is to study the short-term efficacy of the gel, and the short and long-term
safety of the gel and the ointment.
Antepartum Betamethasone Treatment for Prevention of Respiratory Distress in Infants Born by Elective Cesarean Section [Recruiting]
This is a randomized, multicenter, double blind, placebo controlled trial of betamethasone
versus a placebo given prior to the mothers at term and near term gestation (>34 and <40
weeks of gestation) who are scheduled to undergo a planned Cesarean section. The study
design is to determine the efficacy and safety of betamethasone in the prevention of
breathing problems commonly seen in this population.
In infants born by elective Cesarean section, it is hypothesized that antenatal
betamethasone treatment will reduce the risk of neonatal intensive care unit (NICU)
admission from 11% to 8% and/or oxygen therapy +/- positive pressure ventilation (PPV) for
>30 minutes from 4. 5% to 2. 5%.
Comparing the Therapeutic Efficacy of Pimecrolimus Cream With Betamethasone Cream for Discoid Lupus Erythematosus [Completed]
Discoid lupus erythematosus lesions are commonly treated with corticosteroids, but
corticosteroids may induce side effects such as thinning of the skin or scarring. Therefore,
an alternative medication with the same efficacy, but without the side-effects is sought
Pimecrolimus is a newer drug specially designed to treat inflammatory diseases of skin. Its
efficacy in treating discoid lupus erythematosus has not been studied extensively yet.
However studies performed till now show promising results. Long-term topical use of this
medication has not shown any serious side-effects in other skin diseases.
In this study we aimed at comparing pimecrolimus efficacy with that of a common therapeutic
choice, betamethasone valerate 0. 1% cream, to see if pimecrolimus can be used as an
alternative medication in treating discoid lupus erythematosus.
Reports of Suspected Luxiq (Betamethasone Topical) Side Effects
Drug Ineffective (4),
Product Quality Issue (2),
Burning Sensation (2),
Hair Texture Abnormal (1),
Drug Administration Error (1),
Dizziness (1), more >>